Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 3 August 2007. doi:10.1136/thx.2007.082602
Thorax 2008;63:72-77
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society.

CYSTIC FIBROSIS

Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis

A C Young1,2, J W Wilson1,2, T C Kotsimbos1, M T Naughton1,2

1 Department of Allergy Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia
2 Department of Medicine, Monash University, Melbourne, Victoria, Australia

Dr A C Young, Department of Allergy Immunology and Respiratory Medicine, The Alfred Hospital, Commercial Rd, Prahran, Melbourne, VIC, 3181, Australia; alan.young{at}med.monash.edu.au

Background: The clinical benefits of domiciliary non-invasive positive pressure ventilation (NIV) have not been established in cystic fibrosis (CF). We studied the effects of nocturnal NIV on quality of life (QoL), functional and physiological outcomes in CF subjects with awake hypercapnia (arterial carbon dioxide pressure PaCO2>45 mm Hg).

Methods: In a randomised, placebo controlled, crossover study, eight subjects with CF, mean (SD) age 37 (8) years, body mass index 21.1 (2.6) kg/m2, forced expiratory volume in 1 s 35 (8)% predicted and PaCO2 52 (4) mm Hg received 6 weeks of nocturnal (1) air (placebo), (2) oxygen and (3) NIV. The primary outcome measures were CF specific QoL, daytime sleepiness and exertional dyspnoea. Secondary outcome measures were awake and asleep gas exchange, sleep architecture, lung function and peak exercise capacity.

Results: Compared with air, NIV improved the chest symptom score in the CF QoL Questionnaire (mean difference 10; 95% CI 5 to 16; p = 0.002) and the transitional dyspnoea index score (mean difference 3.1; 95% CI 1.2–5.0; p = 0.01). It reduced maximum nocturnal pressure of transcutaneous CO2 (PtcCO2 mean difference –17 mm Hg; 95% CI –7 to –28 mm Hg; p = 0.005) and increased exercise performance on the Modified Shuttle Test (mean difference 83 m; 95% CI 21 to 144 m; p = 0.02). NIV did not improve sleep architecture, lung function or awake PaCO2.

Conclusion: 6 weeks of nocturnal NIV improves chest symptoms, exertional dyspnoea, nocturnal hypoventilation and peak exercise capacity in adult patients with stable CF with awake hypercapnia. Further studies are required to determine whether or not NIV can improve survival.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Balfour-Lynn, I M, Field, D J, Gringras, P, Hicks, B, Jardine, E, Jones, R C, Magee, A G, Primhak, R A, Samuels, M P, Shaw, N J, Stevens, S, Sullivan, C, Taylor, J A, Wallis, C, on behalf of the Paediatric Section of the Home Ox, (2009). BTS guidelines for home oxygen in children. Thorax 64: ii1-ii26 [Full Text]  
  • Noone, P. G (2008). Non-invasive ventilation for the treatment of hypercapnic respiratory failure in cystic fibrosis. Thorax 63: 5-7 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Chest Medicine Jobs

Chest Medicine Jobs